NPEPPS Antibody

What is NPEPPS and what are its principal biological functions?

NPEPPS is an M1 aminopeptidase with broad substrate specificity for several peptides. This enzyme is involved in proteolytic events essential for cell growth and viability, with multiple cellular functions:

• Regulation of neuropeptide activity

• Participation in the antigen-processing pathway for MHC class I molecules

• N-terminal trimming of cytotoxic T-cell epitope precursors

• Digestion of poly-Q peptides found in many cellular proteins

• Processing of tau protein (digests tau from normal brain more efficiently than from Alzheimer disease brain)

NPEPPS is highly conserved and ubiquitously expressed across human tissues, despite being tolerant to genetic modification in experimental models . Its conservation suggests fundamental biological importance, making it a significant target for both basic research and therapeutic development.

What detection methods work best with NPEPPS antibodies?

When working with NPEPPS antibodies, multiple detection approaches can be employed depending on research objectives:

• Western blotting (WB): Most commonly validated method for NPEPPS antibodies, with established protocols for detection in human samples

• Immunohistochemistry (IHC): Useful for examining NPEPPS distribution in tissue sections

• Immunofluorescence (IF): Valuable for subcellular localization studies

• Immunoprecipitation (IP): Essential for studying protein-protein interactions, particularly the NPEPPS-VRAC interactions

For optimal results, researchers should:

• Validate antibody specificity with appropriate controls

• Optimize antibody concentrations for each application

• Consider using multiple antibodies targeting different NPEPPS epitopes to confirm findings

What sample preparation techniques enhance NPEPPS antibody detection?

Effective sample preparation significantly impacts experimental outcomes when working with NPEPPS antibodies:

For protein extraction:

• Use RIPA buffer with protease inhibitor cocktail for most applications

• Consider native extraction methods if studying protein-protein interactions

• Employ subcellular fractionation when investigating compartment-specific functions

• Include phosphatase inhibitors if examining post-translational modifications

For immunohistochemistry:

• Formalin-fixed, paraffin-embedded (FFPE) tissues generally work well

• Consider antigen retrieval methods (typically citrate buffer, pH 6.0)

• Optimize blocking conditions to minimize background

For detecting NPEPPS-VRAC interactions:

• Gentle lysis conditions that preserve protein complexes

• Crosslinking approaches to stabilize transient interactions

• Sequential immunoprecipitation for complex purification

How can researchers effectively study NPEPPS-protein interactions in cancer models?

NPEPPS forms critical protein complexes, particularly with volume regulated anion channels (VRACs), which influence chemotherapy response. To investigate these interactions:

When studying NPEPPS-VRAC interactions specifically:

• Target all five VRAC subunits (LRRC8A-E) that have been shown to interact with NPEPPS

• Compare interaction patterns between chemosensitive and chemoresistant models

• Assess how drug treatment affects the interaction dynamics

What role does NPEPPS play in cancer chemoresistance?

NPEPPS has emerged as a novel mediator of cisplatin resistance, with several mechanisms:

• Regulation of drug uptake:

  • NPEPPS knockdown increases intracellular cisplatin levels in resistant cells

  • Mass cytometry measurements show NPEPPS depletion nearly doubles intracellular cisplatin compared to resistant cells

• Interaction with drug transporters:

  • NPEPPS forms complexes with all VRAC subunits (LRRC8A-E)

  • LRRC8A and LRRC8D are known cisplatin importers

  • Depletion of these VRAC subunits enhances cisplatin resistance

• Therapeutic potential:

  • NPEPPS inhibition with tosedostat re-sensitizes resistant cancer cells to cisplatin

  • This effect is observed in cell lines, xenografts, and patient-derived organoids

The mechanism appears specific to platinum drugs, making NPEPPS a valuable target for overcoming resistance to this important class of chemotherapeutics.

How can NPEPPS activity be quantified in experimental systems?

Measuring NPEPPS enzymatic activity provides insights into its functional state. Researchers can employ:

• Fluorogenic peptide substrates:

  • Use aminopeptidase-specific substrates (e.g., Ala-AMC)

  • Include appropriate controls with specific inhibitors

  • Compare activities in subcellular fractions

• Activity-based protein profiling:

  • Use activity-based probes targeting M1 aminopeptidases

  • Combine with immunoprecipitation to isolate NPEPPS specifically

  • Quantify active enzyme vs. total protein levels

• Cellular assays:

  • Measure intracellular cisplatin accumulation by mass cytometry

  • Quantify cellular responses to tosedostat treatment

  • Assess VRAC function through electrophysiology or volume regulation assays

When interpreting activity data, consider that NPEPPS may have both catalytic and scaffolding functions, particularly in its relationship with VRACs and cisplatin resistance.

What experimental designs best elucidate the mechanism of NPEPPS-mediated chemoresistance?

To thoroughly investigate NPEPPS in chemoresistance:

• Generate appropriate cellular models:

  • Create isogenic cell line pairs (parental/resistant)

  • Develop NPEPPS knockout lines using CRISPR/Cas9

  • Establish stable NPEPPS knockdown with shRNA

  • Generate resistant models through stepwise selection with cisplatin

• Design comprehensive treatment protocols:

  • Test cisplatin alone and in combination with other agents

  • Include tosedostat as a pharmacological NPEPPS inhibitor

  • Examine dose-response relationships and temporal dynamics

  • Evaluate both short-term and long-term responses

• Employ multiple readouts:

  • Measure intracellular drug accumulation (mass cytometry, ICP-MS)

  • Assess DNA damage response markers (γH2AX, p53 activation)

  • Quantify apoptotic markers and cell death

  • Monitor VRAC activity (patch clamp, volume regulation)

• Validate in translational models:

  • Patient-derived xenografts

  • Tumor organoids from resistant patients

  • Correlative studies with clinical specimens

How can researchers distinguish between enzymatic and non-enzymatic functions of NPEPPS?

NPEPPS may function both as an enzyme and as a structural component in protein complexes. To differentiate these roles:

• Use catalytically inactive mutants:

  • Generate point mutations in the active site

  • Compare with wild-type NPEPPS in functional assays

  • Assess whether enzymatic activity is required for cisplatin sensitivity

• Apply selective inhibitors:

  • Use tosedostat at concentrations that specifically inhibit enzymatic activity

  • Compare phenotypes between pharmacological inhibition and genetic depletion

  • Determine if drug effects parallel those of the catalytic mutants

• Employ domain mapping approaches:

  • Create truncation mutants to identify regions required for VRAC interaction

  • Use domain swapping with other M1 aminopeptidases to identify unique functions

  • Determine minimal functional domains for different activities

What are the future directions for NPEPPS antibody applications in cancer research?

NPEPPS antibodies will be instrumental in several emerging research areas:

• Biomarker development:

  • Assessing NPEPPS expression/activity in patient samples

  • Correlating levels with treatment response

  • Developing immunohistochemical protocols for clinical specimens

• Mechanistic studies:

  • Mapping the NPEPPS interactome in different cancer types

  • Visualizing subcellular dynamics during treatment

  • Examining post-translational modifications that regulate function

• Therapeutic development:

  • Target engagement studies for NPEPPS inhibitors

  • Monitoring on-target effects in preclinical models

  • Developing immunoassays for pharmacodynamic measurements

• Immunotherapy connections:

  • Investigating NPEPPS role in antigen presentation

  • Exploring combined NPEPPS inhibition with immunotherapy

  • Examining effects on T cell and NK cell responses

What challenges exist in translating NPEPPS inhibition to clinical applications?

Despite promising preclinical results, several challenges must be addressed:

• Selectivity considerations:

  • NPEPPS belongs to a family of M1 aminopeptidases with similar active sites

  • Current inhibitors like tosedostat target multiple family members

  • Need for more specific inhibitors to reduce off-target effects

• Patient selection strategies:

  • Identifying predictive biomarkers for NPEPPS dependency

  • Determining which cancer types most likely benefit

  • Assessing efficacy in platinum-ineligible patients with carboplatin

• Resistance mechanisms:

  • Potential compensatory pathways when NPEPPS is inhibited

  • Alternative drug uptake/efflux mechanisms

  • Adaptive responses that might limit long-term efficacy

• Clinical trial design:

  • Optimal dosing and scheduling of NPEPPS inhibitors with chemotherapy

  • Appropriate endpoints to measure synergistic effects

  • Biomarker integration for patient stratification

How does NPEPPS function differ between normal and cancer cells?

Understanding context-specific NPEPPS functions is crucial for therapeutic targeting:

• Expression and regulation:

  • NPEPPS is ubiquitously expressed across tissues but may show altered regulation in cancer

  • NPEPPS mRNA increases with cisplatin treatment in both parental and resistant cells

  • Post-translational modifications may differ between normal and cancer cells

• Protein interactions:

  • VRAC-NPEPPS interactions may be altered in chemoresistant cancer cells

  • Cancer-specific interaction partners remain to be fully characterized

  • Structural changes in protein complexes may occur during resistance development

• Functional consequences:

  • Normal cells depend on NPEPPS for protein quality control

  • Cancer cells may co-opt NPEPPS for survival advantage

  • Differential sensitivity to NPEPPS inhibition provides therapeutic window

• Experimental approaches:

  • Compare matched normal and cancer tissues

  • Use isogenic transformation models to track changes in NPEPPS function

  • Employ systems biology approaches to map network alterations